Objective：The effects of continuation of chemotherapy on the quality of life（QOL）of elderly patients with lung cancer have not yet been clearly demonstrated. The aim of this study was to clarify the QOL profiles in elderly patients during chemotherapy in comparison with younger patients.
. Over 60％ of patients are treated with chemotherapy because of their advanced stages at the time of diagnosis. Recent progress in chemotherapy has significantly prolonged the survival of elderly patients with advanced lung cancer compared to best supportive care 2） . However, not only their survival benefit, but also their quality of life （QOL） during treatment needs to be considered when treatment efficacy is evaluated. In fact, QOL was used as the primary endpoint in the Elderly Lung Cancer Vinorelbine Italian Study （ELVIS） trial and the secondary endpoint in various clinical studies for elderly patients with lung cancer 2） -5） . QOL prior to chemotherapy has been reported to be a useful surrogate marker for the prediction of prognosis 6） -8） . However, there are few reports focusing on the effect of continuation of chemotherapy on the QOL of elderly patients with lung cancer 9） -12） . The aim of this study was to clarify the QOL profiles in elderly patients during chemotherapy in comparison with that in younger patients.
P a t i e n t s
A total of 85 patients with advanced lung cancer who received chemotherapy and answered QOL questionnaire at Juntendo University Hospital between August 2000 and January 2007 were retrospectively enrolled in this study. The patients were divided into two groups； group A （n ＝ 49, ≥65 years old, elderly patients） and group B （n ＝ 36, ＜ 65 years old, younger patients） according to the World Health Organization （WHO） ' s definition.
Methods
The efficacy of treatment and adverse events were evaluated with Response Evaluation Criteria in Solid Tumors （RECIST） version 1. 0 and National Cancer Institute -Common Toxicity Criteria （NCI─CTCAE） version 3. 0, respectively. The QOL and performance status （PS） were evaluated with the QOL─anticancer drugs （QOL─ACD） questionnaire and Karnofsky Performance Status （KPS） on the first day of each course of chemotherapy, respectively （Figure─1）. Performance status was determined using the KPS, a physician─completed scale that measured the physical functioning based on level of activity, symptoms of disease and amount of assistance required. It consists of an 11─ point scale, ranging from 0 （dead） to 100 （asymp-tomatic with normal activities）, and categorizes the patients according to their ability to carry out routine work. The QOL─ACD questionnaire consists of 22 items, covering four domains evaluating functional well─being （items 1─6）, physical well─ being （items 7─11）, mental well─being （items 12─ 16）, and psychosocial well─being （items 17─21）. A face scale is used to evaluate global QOL （item 22）
13）14）
. The questionnaires were self─adminis-tered by patients, and the KPS was evaluated by physicians. The total score of each QOL domain and the KPS at each course was compared between group A and group B. Mixed effect models were used for the repeated measurement analysis of variance （ANOVA） data for each QOL score. In order to evaluate whether the QOL score correlated with the KPS scores, we also applied spearman' s correlation coefficient. The Chi─square test was used for between─arm comparisons of categorical variables. A p─value of ＜ 0. 05 was regarded as statistically significant. Statistical analyses were performed using SPSS 16. 0 software. Informed consent for using the QOL questionnaire was obtained from all patients.
Results
The patient characteristics and treatment outcomes are shown in Table─1. There were no significant differences in gender, histology, stage, KPS, and chemotherapeutic regimen received between groups A and B. Interestingly, the response rate, median survival time, and completion rate did not differ among groups （Table─1） . Table─2 shows the hematological and non─hematological toxicities observed in both groups. More cases of hematological toxicity, especially greater than grade 3 or equal leukopenia （p ＝ 0. 04） and neutropenia （p ＝ 0. 02）, were observed in the group A than the group B patients. However, there were no differences in other toxicities between the groups. We also show the compliance for the self─administered QOL questionnaire in both groups （Table─2）. Figure─ 2 A demonstrates the trends in the functional domain scores of the QOL─ACD for both groups during continuation of chemotherapy. The scores of the functional domain during chemotherapy were significantly worse in group A patients than those in group B（ p ＝ 0. 014 by repeated measures ANOVA）. In contrast, there were no significant 507 Juntendo Medical Journal 58（6） ，2012
Figure─1
The QOL data and the KPS collection schedule
The QOL─ACD questionnaires were self─administered by patients, and the KPS was evaluated by physicians at the beginning of each course of chemotherapy.
differences in the scores of other QOL domains （physical, mental, psychosocial, and face scale） in the patients in groups A and B （Figures─2 B, C, D and E） .
The correlation between the KPS and the score for each domain of the QOL─ACD was also investigated. As shown in Table─4, a moderate correlation was observed between the KPS and total score of the functional domain only in the group A patients. （r ＝ 0. 454） .
Discussion
We have clearly demonstrated that the QOL score during chemotherapy, especially for the functional domain, in the elderly patients was significantly lower than that in the younger patients. In our study, there were no significant differences in the patient characteristics, including the baseline QOL score and KPS prior to chemotherapy between elderly patients and younger patients. 
There was also no difference in the chemotherapy regimen administered and median survival time among groups. Therefore, it was difficult to determine why the QOL profile during chemotherapy was different between the elderly and younger patients.
One of the possible reasons could be attributed to the different incidence of adverse effects due to chemotherapy between the two groups. As shown in Table─2, more hematological toxicity, especially greater than grade 3 or equal leucopenia and neutropenia, were observed in elderly patients than in the younger patients. This hypothesis is supported by previous papers indicating that chemotherapy─ induced adverse effects may be more frequently observed in elderly patients than that in younger patients 4） . For example, Langer et al. reported that leukopenia and neuropsychiatric toxicity were more common in elderly males than in younger males 4） . There have been only some studies that have investigated the effect of age on the profile of QOL during chemotherapy 9） -12） . Therefore, whether or not continuation of chemotherapy has a negative impact on QOL during chemotherapy in elderly patients is still controversial. In fact, Hensing et al. have reported that there was no difference in the progression of QOL outcome during carboplatin plus paxlitaxel between patients aged 70 years and older and patients younger than 70 years
12）
. The Vansteenkiste group also indicated that there was no difference in QOL during cisplatin─based chemotherapy between patients aged 65 or over and patients younger than 65
11）
. In contrast, Bazcuk et al. revealed that, not only the global QOL prior to chemotherapy, but also the patient age, influences the degree of change in global QOL 10） . In our study, most of the patients in both groups completed 3 courses of chemotherapy （Table─1； 89. 1％ for elderly patients and 91. 2％ for younger patients, respectively）. However, the compliance in elderly patients at the beginning of 2 courses of chemotherapy （65. 3％） was slightly lower than that in younger patients （83. 3％） （Table─3）. This could be explained by the fact that more cases of hematological toxicity, especially greater than 509 Juntendo Medical Journal 58（6） ，2012
Figure─2 Changes of QOL scores during chemotherapy
The dotted lines and the solid lines indicate the changes for QOL in group A （≥65 years old, n ＝ 49） and group B （＜ 65 years old, n ＝ 36）, respectively. Abbreviations； BC： before chemotherapy, A1C： after the first course of chemotherapy, A2C： after the second courses of chemotherapy, A3C： after the third courses of chemotherapy . Therefore, these results suggest that the QOL in elderly patients in our study could be evaluated better because the data from elderly patients with a poor PS may not have been included in the analysis. In fact, Massimo et al. stated that the entire population of elderly patients may actually have a worse QOL during chemotherapy than suggested by clinical studies, due to the low compliance for QOL questionnaires by elderly patients 6） . We also found that the KPS moderately correlates with the functional domain （Table─4, r ＝ 0. 454）, but not with other domains in elderly patients with lung cancer. This result suggests that the KPS is a simple and reliable surrogate marker for assessing functional QOL in these patients. . To the best of our knowledge, however, no previous reports have ever focused on the difference in the importance of KPS as a surrogate marker for assessing QOL between younger and elderly patients with lung cancer. Therefore, our study could be the first to show that the KPS can be more useful for predicting the QOL in elderly patients than in younger patients. We do not know why the KPS moderately correlates with the QOL in the elderly patients with lung cancer, while it did not correlate with any of QOL categories in the younger patients. It seems that elderly patients with lung cancer directly express their physical condition by their attitude and facial expression, which can be easily evaluated as part of the KPS by physicians. These results suggest that the KPS could be useful for estimating the QOL in elderly patients with lung cancer, because elderly patients are more likely to miss filling out QOL questionnaires.
There is a limitation to our study, in that the chemotherapy regimens used were heterogeneous, which might have influenced the results of the QOL and KPS measurements. However, we still believe that our study is meaningful because 1） there was no statistically significant difference in chemotherapy regimens administered between the two groups, and 2） Tanvetyamon et al. suggested that it seems unlikely that major differences exist in the global QOL associated with standard chemotherapy regimens for advanced non─small cell lung cancer 17） .
In conclusion, we clearly demonstrated that there is difference in the trend in the functional domain of QOL during chemotherapy between elderly and younger patients. Elderly patients with lung cancer should be paid more attention for deterioration of functional QOL and be provided supportive care during chemotherapy than younger patients. This will need to be confirmed by a larger scale study. However, longitudinal data may have some clinical use in determining when treatment needs to be altered, or when discussion of more palliative treatment options should be considered. 
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